ROMVIMZA 14 mg, hard capsule 8 capsules
Active ingredients: VIMSELTINIB, VIMSELTINIB DIHYDRATÉ
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule8 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ROMVIMZA 14 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) OPA : polyamide orienté aluminium PVC avec fermeture de sécurité enfant de 8 gélule(s)
- Marketing authorisation holder
- DECIPHERA PHARMACEUTICALS (NETHERLANDS) (PAYS-BAS)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 16 Mar 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
68364291CIP73032699CIP133400930326992Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| VIMSELTINIBgélule | 14 mg · une gélule | FT |
| VIMSELTINIB DIHYDRATÉgélule | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.